STAT+: Facing a brutal run, battered vaccine makers still see cause for hope

Vaccine makers are expressing cautious optimism despite significant industry disruptions, according to interviews at the BIO international conference this week. These disruptions stem from actions by Health Secretary Robert F. Kennedy Jr., a vocal vaccine critic. Specific impacts include the cancellation of major mRNA vaccine contracts, the dismantling of universal vaccine recommendations, and cuts to government funding for vaccine research. Despite these challenges, some executives believe the industry is adapting and that future developments could offer new avenues for growth. The conference, held in San Diego, provided a platform for these discussions amidst a period of uncertainty for vaccine manufacturers. The sentiment suggests a resilience within the sector, with companies looking for innovative strategies to navigate the evolving landscape of public health policy and funding. While acknowledging the severity of the current challenges, the prevailing mood indicates a determination to overcome obstacles and pursue future opportunities in vaccine development and deployment.